Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Turcot syndrome 1Thymoma 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasm Metastasis 1Mycosis Fungoides 1Multiple Myeloma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphatic Metastasis 1Gallbladder Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1

Interventions

Sunitinib 2Cyclophosphamide 2Celecoxib 2saracatinib 1fludarabine 1entinostat 1belinostat 1avelumab 1alovudine 1MK 2206 1Lapatinib 1FANG vaccine 1Erlotinib Hydrochloride 1AZD 6244 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Thymoma × avelumab × Clear all
NCT03076554 2026-05-29

A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
56 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Thymoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡